Aptevo Therapeutics (APVO) Income from Continuing Operations (2015 - 2026)
Aptevo Therapeutics (APVO) posted Income from Continuing Operations of 7181000.0 for Q1 2026, down 10.78% sequentially from 6482000.0 in Q4 2025, and down 5.23% YoY from 7577415.18 in Q1 2025.
Aptevo Therapeutics (APVO) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Income from Continuing Operations for 12 years, with the latest figure at 7181000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 5.23% year-over-year to 7181000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29219000.0 (down 6.1% YoY) and the FY2025 annual result came in at 32275000.0, down 1.05% from the prior year.
- Income from Continuing Operations declined to 7181000.0 in Q1 2026 per APVO's latest filing, from 6482000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 5934000.0 in Q1 2022 and troughed at 8642000.0 in Q3 2025.
- A 5-year average of 7451352.94 and a median of 7364000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 47.15% in 2022, down 112.35% in 2022.
- Over 5 years, Income from Continuing Operations stood at 8579000.0 in 2022, then grew by 12.22% to 7531000.0 in 2023, then declined by 3.01% to 7758000.0 in 2024, then gained by 16.45% to 6482000.0 in 2025, then decreased by 10.78% to 7181000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 7181000.0, 6482000.0, and 8642000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | -6.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.13 Mn |
| Mar 31, 2026 | -7.18 Mn |
| Dec 31, 2025 | -6.48 Mn |
| Sep 30, 2025 | -8.64 Mn |
| Jun 30, 2025 | -6.91 Mn |
| Mar 31, 2025 | -6.82 Mn |
| Dec 31, 2024 | -7.76 Mn |
| Sep 30, 2024 | -6.25 Mn |
| Jun 30, 2024 | -6.71 Mn |
| Mar 31, 2024 | -7.33 Mn |
| Dec 31, 2023 | -7.53 Mn |
| Sep 30, 2023 | -7.36 Mn |
| Jun 30, 2023 | -8.64 Mn |
| Mar 31, 2023 | -7.87 Mn |
| Dec 31, 2022 | -8.58 Mn |
| Sep 30, 2022 | -8.56 Mn |
| Jun 30, 2022 | -8.11 Mn |
| Mar 31, 2022 | -5.93 Mn |
| Dec 31, 2021 | -4.04 Mn |
| Sep 30, 2021 | -6.01 Mn |